Exelixis, Inc. (EXEL)
EXEL Stock Price Chart
Explore Exelixis, Inc. interactive price chart. Choose custom timeframes to analyze EXEL price movements and trends.
EXEL Company Profile
Discover essential business fundamentals and corporate details for Exelixis, Inc. (EXEL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Apr 2000
Employees
1.15k
Website
https://www.exelixis.comCEO
Michael Morrissey
Description
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EXEL Financial Timeline
Browse a chronological timeline of Exelixis, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $0.86, while revenue estimate is $635.18m.
Earnings released on 5 May 2026
EPS came in at $0.87 surpassing the estimated $0.77 by +13.73%, while revenue for the quarter reached $610.81m , beating expectations by +0.54%.
Earnings released on 10 Feb 2026
EPS came in at $0.94 surpassing the estimated $0.77 by +22.08%, while revenue for the quarter reached $598.66m , beating expectations by +0.36%.
Earnings released on 4 Nov 2025
EPS came in at $0.78 surpassing the estimated $0.69 by +13.87%, while revenue for the quarter reached $597.76m , beating expectations by +1.29%.
Earnings released on 28 Jul 2025
EPS came in at $0.75 surpassing the estimated $0.65 by +15.38%, while revenue for the quarter reached $568.26m , missing expectations by -4.48%.
Earnings released on 13 May 2025
EPS came in at $0.62 surpassing the estimated $0.36 by +73.14%, while revenue for the quarter reached $555.45m , beating expectations by +11.18%.
Earnings released on 11 Feb 2025
EPS came in at $0.55 surpassing the estimated $0.51 by +7.84%, while revenue for the quarter reached $566.76m , beating expectations by +0.63%.
Earnings released on 29 Oct 2024
EPS came in at $0.40 surpassing the estimated $0.35 by +14.29%, while revenue for the quarter reached $539.54m , missing expectations by -3.06%.
Earnings released on 6 Aug 2024
EPS came in at $0.77 surpassing the estimated $0.30 by +156.67%, while revenue for the quarter reached $637.18m , beating expectations by +37.03%.
Earnings released on 30 Apr 2024
EPS came in at $0.17 falling short of the estimated $0.28 by -39.29%, while revenue for the quarter reached $425.23m , missing expectations by -7.68%.
Earnings released on 6 Feb 2024
EPS came in at $0.27 surpassing the estimated $0.21 by +28.57%, while revenue for the quarter reached $479.65m , missing expectations by -0.11%.
Earnings released on 1 Nov 2023
EPS came in at $0.10 matching the estimated $0.10, while revenue for the quarter reached $471.92m , beating expectations by +0.01%.
Earnings released on 1 Aug 2023
EPS came in at $0.25 surpassing the estimated $0.16 by +56.25%, while revenue for the quarter reached $469.85m , beating expectations by +4.96%.
Earnings released on 9 May 2023
EPS came in at $0.12 falling short of the estimated $0.15 by -20.00%, while revenue for the quarter reached $408.79m , missing expectations by -3.61%.
Earnings released on 7 Feb 2023
EPS came in at -$0.03 surpassing the estimated -$0.05 by +40.00%, while revenue for the quarter reached $423.92m , beating expectations by +1.51%.
Earnings released on 1 Nov 2022
EPS came in at $0.23 surpassing the estimated $0.19 by +21.05%, while revenue for the quarter reached $411.74m , beating expectations by +2.05%.
Earnings released on 9 Aug 2022
EPS came in at $0.22 surpassing the estimated $0.19 by +15.79%, while revenue for the quarter reached $419.43m , beating expectations by +7.26%.
Earnings released on 10 May 2022
EPS came in at $0.21 surpassing the estimated $0.14 by +50.00%, while revenue for the quarter reached $355.98m , missing expectations by -4.93%.
Earnings released on 17 Feb 2022
EPS came in at $0.29 surpassing the estimated $0.06 by +383.33%, while revenue for the quarter reached $451.14m , beating expectations by +26.80%.
Earnings released on 2 Nov 2021
EPS came in at $0.12 falling short of the estimated $0.17 by -29.41%, while revenue for the quarter reached $328.42m , missing expectations by -5.01%.
Earnings released on 5 Aug 2021
EPS came in at $0.30 surpassing the estimated $0.06 by +400.00%, while revenue for the quarter reached $385.18m , beating expectations by +30.35%.
EXEL Stock Performance
Access detailed EXEL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
